Your browser doesn't support javascript.
loading
Irinotecan and temozolomide chemotherapy in paediatric and adult populations with relapsed Ewing Sarcoma.
Salah, S; To, Y H; Khozouz, O; Ismail, T; Yaser, S; Alnsour, A; Shahin, O; Sultan, I; Abuhijlih, R; Halalsheh, H; Abuhijla, F; Lewin, J.
Afiliação
  • Salah S; King Hussein Cancer Centre, Amman, Jordan.
  • To YH; Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Khozouz O; King Hussein Cancer Centre, Amman, Jordan.
  • Ismail T; King Hussein Cancer Centre, Amman, Jordan.
  • Yaser S; King Hussein Cancer Centre, Amman, Jordan.
  • Alnsour A; King Hussein Cancer Centre, Amman, Jordan.
  • Shahin O; King Hussein Cancer Centre, Amman, Jordan.
  • Sultan I; UT MD Anderson Cancer Centre, Huston, TX, USA.
  • Abuhijlih R; King Hussein Cancer Centre, Amman, Jordan.
  • Halalsheh H; King Hussein Cancer Centre, Amman, Jordan.
  • Abuhijla F; King Hussein Cancer Centre, Amman, Jordan.
  • Lewin J; King Hussein Cancer Centre, Amman, Jordan.
Clin Transl Oncol ; 23(4): 757-763, 2021 Apr.
Article em En | MEDLINE | ID: mdl-32761317
BACKGROUND: Irinotecan and temozolomide (IT) is a widely used regimen for relapsed Ewing sarcoma (ES), although studies are largely limited to paediatric populations. METHODS: We retrospectively reviewed paediatric (< 18 years) and adult patients (≥ 18 years) treated with salvage IT at two institutions. Haematologic toxicities were graded according to common terminology criteria of adverse events. Survival was estimated by the Kaplan-Meier method and compared by the Log Rank test. RESULTS: Fifty-three patients were treated with IT from Jan, 2010 to Dec, 2018 (n = 16 paediatric; n = 37 adult). IT was given as second-line (n = 34; 64%) or ≥ third-line (n = 19; 36%). There was no difference in ≥ grade 3/4 haematologic toxicity between paediatrics and adults (31% vs. 35% respectively; p = 0.76). The frequency of diarrhoea of any grade was similar (38% in each group). Of 43 patients assessable for response, 12 (28%) had objective response (1 CR, 11 PR), 12 (28%) stable disease and 19 (44%) disease progression. Objective response rate did not differ between the two groups (36% in paediatrics vs. 25% in adults; p = 0.47). Median PFS was superior in paediatrics vs. adults (7.4 vs. 2.2 months, p = 0.039). CONCLUSION: Irinotecan and temozolomide (IT) chemotherapy has activity for relapsed ES, with favourable toxicity and equally observed objective responses in the paediatric and adult populations. The observed superior PFS for the paediatric cohort requires further confirmation in future studies.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcoma de Ewing / Neoplasias Ósseas / Protocolos de Quimioterapia Combinada Antineoplásica / Irinotecano / Temozolomida / Recidiva Local de Neoplasia Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Child / Humans Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Jordânia País de publicação: Itália
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcoma de Ewing / Neoplasias Ósseas / Protocolos de Quimioterapia Combinada Antineoplásica / Irinotecano / Temozolomida / Recidiva Local de Neoplasia Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Child / Humans Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Jordânia País de publicação: Itália